Pharmaceutical company Oramed Pharmaceuticals Inc (NASDAQ:ORMP) (TASE:ORMP) reported on Wednesday the receipt of a milestone payment of USD3m for ORMD-0801 under a prior license and investment agreement with Hefei Tianhui Incubator of Technologies Co Ltd (HTIT).
To date, Oramed has received a total of USD33m in payments for ORMD-0801 from HTIT.
China is currently the largest single diabetes population in the world, stated Oramed CEO Nadav Kidron. We are very pleased with the continuing development of our partnership with HTIT in bringing ORMD-0801 to this important market.
In addition, Oramed is seeking to revolutionise the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). It has completed multiple Phase II clinical trials under an Investigational New Drug application with the US Food and Drug Administration.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial